methyl 7-<1'-(2'-pyrrolidinyl)-5'-carboxaldehyde>heptanoate | 60289-35-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: methyl 7-<1'-(2'-pyrrolidinyl)-5'-carboxaldehyde>heptanoate
• 英文别名: 1-(6-Methoxycarbonylhexyl)-2-oxopyrrolidin-5-carboxaldehyd；dl-1-(6-methoxycarbonylhexyl)-5-formyl-2-pyrrolidone；Methyl 7-(2-formyl-5-oxopyrrolidin-1-YL)heptanoate
• CAS: 60289-35-2
• 化学式: C₁₃H₂₁NO₄
• 分子量: 255.314
• InChiKey: COYUAWIJCNCEKE-UHFFFAOYSA-N

物化性质

• 沸点：
  400.8±40.0 °C(Predicted)
• 密度：
  1.145±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  18
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.77
• 拓扑面积：
  63.7
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl 7-<1'-(2'-pyrrolidinyl)-5'-carboxaldehyde>heptanoate 在 sodium tetrahydroborate 、 溴 、 sodium hydride 、 potassium carbonate 作用下， 以 乙醇 为溶剂， 反应 8.75h， 生成
  参考文献：
  名称：

  Baraldi; Simoni; Casolari, Farmaco, Edizione Scientifica, 1983, vol. 38, # 7, p. 498 - 507

  摘要：

  DOI：
• 作为产物：
  描述：

  7-(2-hydroxymethyl-5-oxo-pyrrolidin-1-yl)-heptanoic acid methyl ester 在 吡啶 作用下， 生成 methyl 7-<1'-(2'-pyrrolidinyl)-5'-carboxaldehyde>heptanoate
  参考文献：
  名称：

  8-Azaprostanoic acid derivatives

  摘要：

  揭示了一种新的8-azaprostanoic酸衍生物及其制备方法。所述的8-azaprostanoic酸衍生物由以下公式表示：##STR1##其中R.sup.1为氢或2至6个碳原子的烷基，R.sup.2为氢或甲基，R.sup.3为氢，或者当R.sup.2为氢且R.sup.3为甲基时，R.sup.1为甲基。它们表现出类似前列腺素的活性，可用作支气管扩张剂、催产剂、引产或助产剂，以及/或用于治疗胃肠道疾病。

  公开号：

  US04113873A1

文献信息

• LACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS
  申请人：CAYMAN CHEMICAL COMPANY, INC.

  公开号：US20160060216A1

  公开（公告）日：2016-03-03

  Disclosed herein are compounds of formula (I) wherein L 1 , L 2 , L 3 , L 4 , R 1 , R 4 , R 5 , R 6 , and s are as defined in the specification. Compounds of formula (I) are EP 4 agonists useful in the treatment of glaucoma, osteoporosis, bone fracture, periodontal bone loss, orthopedic implant, alopecia, neuropathic pain, and related disorders. Pharmaceutical compositions and methods of treating conditions or disorders are also described.

  披露了公式(I)的化合物 其中L 1 , L 2 , L 3 , L 4 , R 1 , R 4 , R 5 , R 6 ，和s如说明书所定义。 公式(I)的化合物是EP 4 激动剂，用于治疗青光眼、骨质疏松症、骨折、牙周骨丢失、矫形植入物、脱发、神经性疼痛和相关的疾病。 还描述了药物组合物和治疗条件或疾病的方法。
• 8-Aza-11-deoxy prostaglandin analogues
  申请人：——

  公开号：US20030120079A1

  公开（公告）日：2003-06-26

  This invention relates to compounds which are generally EP 4 receptor agonists and which are represented by Formula I: 1 wherein A is a —CH 2 —CH 2 —, or —CH═CH—; B is absent, an aryl, or heteroaryl group; R 1 is alkyl, alkenyl, alkynyl, cycloalkylalkyl, heterocyclylalkyl, aryl, arylalkyl or heteroaryl, when B is aryl or heteroaryl and R 3 , R 4 , R 5 and R 6 are not simultaneously hydrogen, or R 1 is heterocyclylalkyl, aryl, or heteroaryl when B is absent and R 3 , R 4 , R 5 and R 6 are simultaneously hydrogen; and the other substituents are as defined in the specification; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, methods for their use as therapeutic agents, and methods of preparation thereof.

  本发明涉及一般为EP4受体激动剂的化合物，其表示为式I：其中A为—CH2—CH2—，或—CH═CH—；B为不存在、芳基或杂芳基；R1为烷基、烯烃基、炔烃基、环烷基烷基、杂环烷基烷基、芳基、芳基烷基或杂芳基，当B为芳基或杂芳基且R3、R4、R5和R6不同时为氢时，或者R1为杂环烷基烷基、芳基或杂芳基，当B为不存在且R3、R4、R5和R6同时为氢时；其他取代基如规范中所定义；或其单体异构体、消旋或非消旋异构体混合物，或其药学上可接受的盐或溶剂。该发明还涉及含有此类化合物的药物组合物、用作治疗剂的方法以及其制备方法。
• METHODS, SYSTEMS, AND COMPOSITIONS FOR PROMOTING BONE GROWTH
  申请人：CAYMAN CHEMICAL COMPANY, INC.

  公开号：US20160158413A1

  公开（公告）日：2016-06-09

  The present invention relates to novel bone compositions for locally delivering a therapeutic agent to the site of a bone defect. Therapeutic agents may promote repair of the bone defect and/or treat conditions or disorders such as pain, inflammation, cancer, and infection. The compositions include calcium phosphate cements and a demineralized bone matrix or a collagen sponge. The compositions are useful for implantation in a patient at the site of a bone defect.

  本发明涉及一种新型骨组成物，用于局部向骨缺损部位提供治疗剂。治疗剂可以促进骨缺损的修复和/或治疗疼痛、炎症、癌症和感染等病症或疾病。该组成物包括磷酸钙水泥和脱矿骨基质或胶原海绵。该组成物可用于患者的骨缺损部位植入。
• Methods, systems, and compositions for promoting bone growth
  申请人：Cayman Chemical Company, Inc.

  公开号：US10729810B2

  公开（公告）日：2020-08-04

  The present invention relates to novel bone compositions for locally delivering a therapeutic agent to the site of a bone defect. Therapeutic agents may promote repair of the bone defect and/or treat conditions or disorders such as pain, inflammation, cancer, and infection. The compositions include calcium phosphate cements and a demineralized bone matrix or a collagen sponge. The compositions are useful for implantation in a patient at the site of a bone defect.

  本发明涉及用于向骨缺损部位局部输送治疗剂的新型骨组合物。治疗剂可促进骨缺损的修复和/或治疗疼痛、炎症、癌症和感染等疾病。组合物包括磷酸钙骨水泥和脱矿骨基质或胶原海绵。这些组合物可用于植入患者骨缺损部位。
• Zoretic, P. A.; Bhakta, C.; Jardin, J., Journal of Heterocyclic Chemistry, 1983, vol. 20, p. 465 - 466
  作者：Zoretic, P. A.、Bhakta, C.、Jardin, J.

  DOI：——

  日期：——